Survival Arts

"Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes"

Forwarded to me by Perry Metzger, and independently brought to my attention by Tom Burroughes, published in Science as "Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes":

Using adoptive transfer of lymphocytes given after host immunodepletion it is possible to mediate objective cancer regression in patients with metastatic melanoma. However, the generation of tumor-specific T cells in this mode of immunotherapy is often limiting. Using a retrovirus encoding a T cell receptor, we report here the ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood. Adoptive transfer of these transduced cells in fifteen patients resulted in durable engraftment at levels exceeding ten percent of peripheral blood lymphocytes for at least two months post infusion. We observed high sustained levels of circulating, engineered cells at one year post-infusion in two patients, that both demonstrated objective regression of metastatic melanoma lesions. This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer.

I have the full paper, forwarded to me by a friend, which I'm reading slowly.

Posted by Russell Whitaker at September 4, 2006 09:00 PM | TrackBack